<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-03T11:21:30+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>mRNA疫苗上市关键：安全性和有效性评价方法的建立丨医麦新观察</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/Q0zXOw8IGiKVfV5sawAZLg</id>
    <link href="https://mp.weixin.qq.com/s/Q0zXOw8IGiKVfV5sawAZLg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智享生物顺利通过欧盟QP审计，助力全球生物药研发和生产丨医麦猛爆料</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/qLCMeZ09MUZYpGw2RdGVCA</id>
    <link href="https://mp.weixin.qq.com/s/qLCMeZ09MUZYpGw2RdGVCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>针对多种实体瘤有效的广谱抗癌药物在美获批新适应症，国内也即将上市丨医麦新观察</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/WVK6sX8n5owqx6iDJBvSHg</id>
    <link href="https://mp.weixin.qq.com/s/WVK6sX8n5owqx6iDJBvSHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>对话复星医药回爱民博士：mRNA新冠核酸疫苗BNT162b2最新研发进展</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/ouZ8-Phku70HdHx87dh0kA</id>
    <link href="https://mp.weixin.qq.com/s/ouZ8-Phku70HdHx87dh0kA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！辉瑞/BioNTech合作开发的疫苗获得英国紧急使用授权丨医麦猛爆料</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/zZ6HT07LslYF7zR-cbLjHg</id>
    <link href="https://mp.weixin.qq.com/s/zZ6HT07LslYF7zR-cbLjHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>钱文斌教授：携带IL-7/CCL19的第四代CAR-T治疗B细胞淋巴瘤疗效优异，值得期待</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/H0h8feHCkBxgO0Kk4u7A-g</id>
    <link href="https://mp.weixin.qq.com/s/H0h8feHCkBxgO0Kk4u7A-g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品审评只发补一次，《药品审评中心补充资料工作程序（试行）》正式实施丨医麦猛爆料</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/SU7V9jlzX0zUjGg0zm6yDw</id>
    <link href="https://mp.weixin.qq.com/s/SU7V9jlzX0zUjGg0zm6yDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>丹纳赫生命科学隆重发布使命宣言和精准医学解决方案</title>
    <updated>2020-12-02T21:53:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/SVcBX_Xb6oYQoz-1EWnCwA</id>
    <link href="https://mp.weixin.qq.com/s/SVcBX_Xb6oYQoz-1EWnCwA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CRISPR荣获诺奖！基因编辑研究方向全面盘点，一文带你了解基因魔剪的前世今生丨医麦新观察</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/wfOnesGHk8DYxwmQjaImvg</id>
    <link href="https://mp.weixin.qq.com/s/wfOnesGHk8DYxwmQjaImvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>首家亚洲CAR-T商业化生产工厂，诺华的CAR-T细胞治疗亚太地区布局丨医麦猛爆料</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/DonvAMPgmiJW5AprQILWSQ</id>
    <link href="https://mp.weixin.qq.com/s/DonvAMPgmiJW5AprQILWSQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>基因治疗先驱与再生元达成合作，开发抗体“鸡尾酒”新疗法丨医麦猛爆料</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/Kghe63XVmvrhTVveIxAR7g</id>
    <link href="https://mp.weixin.qq.com/s/Kghe63XVmvrhTVveIxAR7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州超4亿美元引进的HER2双特异性抗体在美获突破性疗法称号丨医麦猛爆料</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/cBFnrW4LwFBwgVg8KQEc4Q</id>
    <link href="https://mp.weixin.qq.com/s/cBFnrW4LwFBwgVg8KQEc4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」硕世生物副董事长王国强：精准医学是未来大趋势，行业发展需全产业共同发力</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/QFGoFTSyXmIwqj3yMApigg</id>
    <link href="https://mp.weixin.qq.com/s/QFGoFTSyXmIwqj3yMApigg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>李玉华教授:CAR-T​桥接DC疫苗输注疗效显著，或是CAR-T联合治疗策略新方向</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/6FOgqJ59OoHpo_nWIm4NdA</id>
    <link href="https://mp.weixin.qq.com/s/6FOgqJ59OoHpo_nWIm4NdA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨3000万美元A轮融资，推进“零件/模块化”在体CRISPR基因编辑疗法开发</title>
    <updated>2020-12-02T07:55:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/Lr8jN7eOlX8bCPV5LQdqkw</id>
    <link href="https://mp.weixin.qq.com/s/Lr8jN7eOlX8bCPV5LQdqkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>晶准生物创始人谈静泉博士谈纳米抗体药物研发：“两大原则”破解多次跨膜药靶难题丨医麦猛爆料</title>
    <updated>2020-11-30T23:02:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/RiVm8dFc0NHHQukY-W2Wag</id>
    <link href="https://mp.weixin.qq.com/s/RiVm8dFc0NHHQukY-W2Wag" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第三款突破性疗法称号CAR-T？科济生物的BCMA CAR-T疗法拟纳入突破性治疗品种丨医麦猛爆料</title>
    <updated>2020-11-30T23:02:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/G7dWC3TeIEjS0XP5JRbUAw</id>
    <link href="https://mp.weixin.qq.com/s/G7dWC3TeIEjS0XP5JRbUAw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>上海医药CD20抗体获CDE受理，细数CD20抗体药物发展史丨医麦新观察</title>
    <updated>2020-11-30T23:02:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/X_PbHnoUwrAsFLixodxGLg</id>
    <link href="https://mp.weixin.qq.com/s/X_PbHnoUwrAsFLixodxGLg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邱录贵教授：中国MM CAR-T研究占国际同类研究半壁江山，未来应加强前瞻性、大系列、多中心的临床研究</title>
    <updated>2020-11-30T23:02:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/kOSpgQx7s3QBr8ifTHBUtQ</id>
    <link href="https://mp.weixin.qq.com/s/kOSpgQx7s3QBr8ifTHBUtQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」明码生物科技总经理孙乐乐：基因测序领域有两大挑战，目标做中国最好的测序公司</title>
    <updated>2020-11-30T23:02:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/mRcanmvJMZv-TLJAM5yAEg</id>
    <link href="https://mp.weixin.qq.com/s/mRcanmvJMZv-TLJAM5yAEg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>